• SHC-1 Inhibition and CFTR Surface Trafficking

  2026-10-01

  A 2026 study shows that MAPK/SHC-1-dependent CFTR internalization is conserved in airway and intestinal epithelial models, but pharmacological increases in surface CFTR are strongly cell-type dependent. The work also finds that idebenone and compound 110#3 alter unrelated plasma-membrane proteins in CFBE cells, emphasizing the need to distinguish CFTR-specific trafficking from broader membrane remodeling.

• Halazone Workflows for Water and Sodium Channels

  2026-10-01

  Halazone supports two sharply different research workflows: rapid oxidative water disinfection and controlled perturbation of sodium-current inactivation in myelinated nerve fibers. This practical guide connects concentration selection, assay controls, stability management, and troubleshooting without treating water-treatment results as proof of neurophysiological or clinical safety.

• VE-821 ATR Kinase Inhibitor Guide

  2026-09-30

  VE-821 is a selective, ATP-competitive ATR kinase inhibitor for DNA damage response and DNA repair pathway research. It suppresses ATR-dependent Chk1 signaling and can increase radiosensitivity and chemotherapy sensitization in experimental cancer models.

• Stable Yeast Expression of Exendin-4: Study Analysis

  2026-09-30

  The 2024 Frontiers in Systems Biology study investigated recombinant Exendin-4 production in Escherichia coli and chromosomally integrated Saccharomyces cerevisiae. Detection of Exendin-4 at the expected size and confirmation by immunoassay support yeast as a platform for further research on more accessible GLP-1 receptor agonist production, while purification, bioactivity, safety, and therapeutic performance remain unresolved.

• Tankyrase Inhibition and Hippo Signaling in HCC

  2026-09-29

  The reference study identifies a mechanism by which tankyrase inhibitors restrain hepatocellular carcinoma growth: suppression of YAP activity through increased AMOTL1 and AMOTL2, linking tankyrase biology to the Hippo cascade. Its cell-based evidence also supports combining tankyrase inhibition with MEK or AKT pathway inhibition, while defining important limits for translating these findings to other tumor types.

• E-PLUS Trial: Elobixibat for Colonoscopy Preparation

  2026-09-29

  The E-PLUS study protocol introduces a randomized, multicentre noninferiority comparison of elobixibat hydrate plus sodium picosulfate/magnesium citrate against split-dose polyethylene glycol with ascorbic acid for outpatient colonoscopy preparation. Although the protocol does not report efficacy results, its patient-centered endpoint framework addresses the trade-off between cleansing quality, tolerability, and adherence.

• Verteporfin Workflows for Mechanobiology and PDT

  2026-09-28

  Verteporfin (CL 318952) supports a dual experimental strategy: light-dependent photodynamic injury and light-independent disruption of p62-linked autophagy. This guide translates those properties into reproducible apoptosis, autophagy, ocular neovascularization, and exploratory cancer-mechanobiology workflows.

• Canagliflozin Remodels Renal Mitochondria in Mice

  2026-09-28

  In a hypertensive, streptozotocin-induced diabetic mouse model, canagliflozin was associated with improved proximal tubular mitochondrial structure and bioenergetics, with stronger functional effects in males than females. The study connects SGLT2 inhibition with renal mitochondrial remodeling, while leaving open whether these changes directly mediate kidney protection or depend on sex, glycemic effects, or model context.

• ALC-0159 in mRNA LNPs and PET Tracking

  2026-09-27

  ALC-0159 is a PEG-conjugated lipid excipient used in lipid nanoparticle formulations for mRNA delivery. A 2025 PET reporter study tracked expression of an mRNA-encoded antigen, but it does not establish product-specific performance for ALC-0159.

• LG 101506 and the PD-L1 Stability Question

  2026-09-26

  Explore how LG 101506, an RXR modulator, can support carefully controlled studies of nuclear receptor signaling alongside research into PD-L1 stability. This article connects the experimental logic without implying a mechanism that the evidence has not established.

• CHIR 99021 Trihydrochloride: Reading Organoid State

  2026-09-25

  CHIR 99021 trihydrochloride is a potent GSK-3 inhibitor whose effects in organoids depend on cell state, pathway context, and assay timing. This article connects the compound’s pharmacology to a tunable human intestinal organoid study and shows how to design experiments that distinguish stem-cell expansion from lineage change.

• A Tunable Human Intestinal Organoid System

  2026-09-25

  A human small-intestinal organoid study shows that increasing stem-cell competence can support both ongoing proliferation and greater epithelial diversity in a shared culture condition. The authors also demonstrate that cell-fate balance can be shifted using BET inhibition or selected niche signals, offering a more flexible framework for organoid expansion and differentiation studies.

• Fritillaria Alkaloids Suppress LPS-Driven Inflammation

  2026-09-24

  A study of four isosteroidal alkaloids from Fritillaria reports reduced inflammatory readouts in LPS-treated RAW264.7 cells, alongside changes in MyD88- and TRIF-linked signaling. Ebeiedinone and peimisine were also evaluated in a rat acute lung injury model, extending the findings beyond cell culture while leaving questions about pathway causality and clinical transferability open.

• Glucagon–GLP-1R Crosstalk Revealed by FRET

  2026-09-24

  Chepurny and colleagues used cAMP-sensitive FRET assays and molecular modeling to show that glucagon can activate the GLP-1 receptor, challenging the assumption that these related receptors respond only to their canonical ligands. Their antagonist comparisons and cellular validation highlight the need to test receptor selectivity directly, especially when interpreting multi-receptor pharmacology and metabolic regulation studies.

• Anagliptin (SK-0403) in Viability Assays

  2026-09-23

  A practical guide to using Anagliptin (SK-0403), SKU BA7300, as a DPP-4 inhibitor in cell-based research without confusing target engagement with viability. It connects product handling and assay controls with published evidence for anagliptin’s vascular effects, while clearly distinguishing established findings from workflow recommendations.

7939 records 1/530 page Next 12345 下5页 Last page